20571-15-7

Basic information

• Product Name: spiro[2.3]hexan-4-one
• Synonyms: spiro[2.3]hexan-4-one;spiro[2.3]hexan-6-one
• CAS NO: 20571-15-7
• Molecular Formula: C6H8O
• Molecular Weight: 96.12712
• Mol File: 20571-15-7.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 25 °C(Press: 2 Torr)
• Appearance: /
• Density: 1.09±0.1 g/cm3(Predicted)
• CAS DataBase Reference: spiro[2.3]hexan-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: spiro[2.3]hexan-4-one(20571-15-7)
• EPA Substance Registry System: spiro[2.3]hexan-4-one(20571-15-7)

Safety Data

• Hazardous Substances Data: 20571-15-7(Hazardous Substances Data)

Usage

General Description

Spiro[2.3]hexan-4-one is a chemical compound with a spirocyclic structure, meaning it has two rings that share a single common atom. It is also known as 4-methyl-1-cyclohexanone or 4-methylcyclohexan-1-one. Spiro[2.3]hexan-4-one is a cyclic ketone, which means it contains a carbonyl group within a ring structure. It is commonly used as a building block in organic synthesis and plays a role in the production of a variety of pharmaceuticals, agrochemicals, and other fine chemicals. Spiro[2.3]hexan-4-one also has applications in the flavor and fragrance industry, where it contributes to the scent of various products. Additionally, it is known to exhibit anti-inflammatory and anti-fungal properties, making it of interest for potential medicinal uses.

Upstream product

• 27567-82-4 bicyclopropylidene 
• 18914-34-6 1-methylenespiro[2.2]pentane 
• 39546-97-9 Bis(trimethylsilyoxy)-1,1'-bicyclopropyl 
• 39762-73-7 Sulfuryldioxy-1,1'-bicyclopropyl 
• 73496-25-0 C₁₄H₁₃N₃O₂ 
• 52952-63-3 7-oxatrispiro<2.0.2.1>heptane 
• 33509-32-9 1-bromo-4-chlorobicyclo<2.2.0>hexane 

Downstream Products

• 445306-48-9 5-amino-spiro[2.3]hexane-5-carboxylic acid ethyl ester 
• 21426-37-9 Dispiro <2.0.2.2.>octan 

Relevant articles and documents

Hepatitis C virus inhibitors

The present invention relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmaceutical compositions containing such analogs and methods for using these analogs in the treatment of HCV infection.

Hepatitis C virus inhibitors

The present invention relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmaceutical compositions containing such analogs and methods for using these analogs in the treatment of HCV infection.